Marubeni Pharmaceuticals Corporation (Head Office: Tokyo; President: Shigeyuki Nishinaka; hereinafter “Marubeni Pharmaceuticals”) announced today that its Chinese subsidiary, Marubeni Pharmaceuticals (Suzhou) Co., Ltd. (Head Office: Suzhou, Jiangsu Province, People’s Republic of China; Chairman and President: Yoshitaka Koketsu; hereinafter “Marubeni Pharmaceuticals (Suzhou)”), has launched XENLETA® injection (generic name: lefamulin acetate; hereinafter “XENLETA”) in China on February 3, 2026.
XENLETA was approved by the National Medical Products Administration (NMPA) of China on June 30, 2025, for the treatment of adult community-acquired pneumonia, and was added to China’s National Reimbursement Drug List (NRDL) in December 2025. In addition, tablets containing the same active ingredient are scheduled to be launched in or after April 2026.
Through the launch of XENLETA injection in China, Marubeni Pharmaceuticals and Marubeni Pharmaceuticals (Suzhou) aim to provide a new treatment option for adult community-acquired pneumonia and further contribute to the management of infectious diseases in China.
【Reference】: About XENLETA® (generic name: lefamulin acetate)
XENLETA is a pleuromutilin-class antibiotic discovered and developed by Nabriva Therapeutics plc (Head Office: Dublin, Ireland; hereinafter “Nabriva”). With a mechanism of action distinct from existing antibiotics, XENLETA is designed to inhibit bacterial protein synthesis essential for bacterial growth by binding with high affinity and specificity to a molecular site different from those targeted by other antibiotics, thereby reducing the likelihood of resistance and cross-resistance.
XENLETA is currently approved for the treatment of adult community-acquired pneumonia by the U.S. Food and Drug Administration (FDA), Health Canada, and the European Commission (EC), and is marketed under the brand name XENLETA® in the United States.
Marubeni Pharmaceuticals (Suzhou) (formerly Sumitomo Pharma (Suzhou) Co., Ltd.) obtained exclusive development and commercialization rights for XENLETA in Mainland China, Taiwan, Hong Kong, and Macau in May 2021. Subsequently, in July 2023, Sumitomo Pharma Co., Ltd. acquired the assets related to XENLETA for these territories from Nabriva. In July 2025, Marubeni Pharmaceuticals succeeded to these rights from Sumitomo Pharma Co., Ltd.
<Contact for inquiries>
Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
TEL: +86-512-6283-1082
